Evidence map›Paper›PMID 40675873›Full record

Trial reportEuropean urology oncology2025

Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial.

Ryan M Phillips, James A Proudfoot, Elai Davicioni, Yang Liu, Daniel E Spratt, Jeff M Simko, Robert B Den, Alan Pollack, Seth A Rosenthal, A Oliver Sartor and 12 more

Registry-linked trialAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European urology oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00288080 (A Phase III Protocol of Androgen Suppression), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00288080 phase3completednot on this map

A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT Vs AS and 3DCTR/IMRT Followed by Chemotherapy With Docetaxel and Prednisone for Localized, High-Risk, Prostate Cancer

TypeinterventionalSponsorRadiation Therapy Oncology GroupRan2005 to 2022Enrolled612ConditionsProstate CancerArmsDexamethasone, Prednisone, docetaxel, Oral antiandrogen, Radiation therapy
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Ryan M PhillipsMayo Clinic, Rochester, MN, USA. Electronic address: phillips.ryan@mayo.edu.
James A ProudfootVeracyte, San Diego, CA, USA.
Elai DavicioniVeracyte, San Diego, CA, USA.
Yang LiuVeracyte, San Diego, CA, USA.
Daniel E SprattUniversity Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Jeff M SimkoUniversity of California-San Francisco, San Francisco, CA, USA.
Robert B DenThomas Jefferson University Hospital, Philadelphia, PA, USA.
Alan PollackUniversity of Miami Health Systems, Miami, FL, USA.
Seth A RosenthalDepartment of Radiation Oncology, Sutter Medical Group, Sacramento, CA, USA.
A Oliver SartorMayo Clinic, Rochester, MN, USA.
Christopher J SweeneySouth Australian Immunogenomics Cancer Institute, Adelaide, Australia.
Gerhardt AttardUniversity College London, London, UK.
Leslie LongoriaUniversity of California-San Francisco, San Francisco, CA, USA.
Samir PatelCross Cancer Institute, University of Alberta, Edmonton, Canada.
Michael W StrazaMedical College of Wisconsin, Milwaukee, WI, USA.
Jason A EfstathiouMassachusetts General Hospital, Boston, MA, USA.
Amit B ShahWellspan Health, York, PA, USA.
Karen E HoffmanUniversity of Texas MD Anderson Cancer, Houston, TX, USA.
Joseph P RodgersAmerican College of Radiology, Philadelphia, PA, USA; NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA.
Howard M SandlerCedars-Sinai, Los Angeles, CA, USA.
Felix Y FengUniversity of California-San Francisco, San Francisco, CA, USA.
Phuoc T TranUniversity of Maryland, Baltimore, MD, USA. Electronic address: phuoc.tran@umm.edu.

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Elaina Harper · 2014 to 2026
$146.4M
IROC: Enhancing local enrolling site radiological data capture capabilities for NCTN trialsU24CA180803 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI Thomas J. FitzGerald, MICHAEL V KNOPP · 2014 to 2026
$116.2M
NRG Oncology Biospecimen BankU24CA196067 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Tanner J. Freeman, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$42.6M
Resource Sharing CoreU54CA273956 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Amit Sawant, Nicole L Simone · 2022 to 2026
$8.9M
Tumor-barcoding coupled with high-throughput sequencing of a novel chemoradiation resistant SCLC mouse modelU01CA231776 · NCI · JOHNS HOPKINS UNIVERSITY · PI HANN, CHRISTINE L., MARCHIONNI, LUIGI · 2018 to 2022
$3.9M
Integrating bioinformatics into multiscale models for hepatocellular carcinomaU01CA212007 · NCI · JOHNS HOPKINS UNIVERSITY · PI EWALD, ANDREW JOSEF, FERTIG, ELANA · 2018 to 2022
$3.2M
Tumor-barcoding coupled with high-throughput sequencing for quantitative radiogenomics of the abscopal response in NSCLCR01CA271540 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Phuoc T. Tran · 2023 to 2026
$2.3M
NCI NIH HHS R01 CA271540NCI NIH HHS U01 CA212007NCI NIH HHS U01 CA231776NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS U24 CA180803NCI NIH HHS U24 CA196067NCI NIH HHS U54 CA273956
6 · The paper itself

Abstract

BACKGROUND AND

objectiveNRG/RTOG 0521 randomized men with high-risk localized prostate cancer (PC) to androgen suppression (AS) and definitive radiotherapy (RT) ± docetaxel-based chemotherapy (CT). The overall survival (OS) benefit with CT initially reported was lost on longer follow-up. The Decipher genomic classifier (GC) measures multiple transcripts relevant to docetaxel action. Basal/luminal differentiation portends differential response to AS and CT for high-risk localized and metastatic hormone-sensitive PC. We validated the Decipher GC in pretreatment biopsy samples for risk stratification and examined basal-luminal subtyping to predict docetaxel response.

methodsDecipher GC scores and basal-luminal cellular subtypes were generated for specimens from NRG/RTOG 0521. The primary objective was to validate the independent prognostic ability of GC for metastasis-free survival (MFS). Treatment effects in luminal proliferating (LP) and non-LP cell subtypes were examined in relation to MFS, OS, and distant metastasis (DM). KEY FINDINGS AND LIMITATIONS: Samples were obtained from 283 patients and yielded 183 GC scores. Over median follow-up of 9.9 yr, 67 metastasis events were observed, including 34 DM events. Multivariable analysis revealed that GC was independently associated with DM (subdistribution hazard ratio 1.45) and MFS (hazard ratio 1.20). No biomarker-by-treatment interaction with GC and docetaxel was detected. The 10-yr restricted mean survival time difference in OS with CT was 13.7 mo for LP (p = 0.053) and 2.5 mo for non-LP (p = 0.63) tumors. CONCLUSIONS AND CLINICAL IMPLICATIONS: The Decipher GC score was independently associated with DM and MFS, and LP tumors may benefit from addition of CT. Validation of these findings may allow more effective use of CT in men with localized PC. The original NRG/RTOG 0521 trial is registered on ClinicalTrials.gov as NCT00288080.

Indexed as

Androgen AntagonistsProstatic NeoplasmsTaxoidsAgedChemoradiotherapyDocetaxelGene Expression ProfilingHumansMaleMiddle AgedPrognosisTranscriptomeAndrogen AntagonistsDocetaxelTaxoidsBiomarkerChemotherapyProstateRadiationTranscriptome

Identifiers

PMID40675873
PMCPMC12370384

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.